Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands.
Frank D VerbraakDirk L PonsioenOdette A M Tigchelaar-BeslingVuong NguyenMark C GilliesDaniel BarthelmesCaroline C W KlaverPublished in: Acta ophthalmologica (2020)
Starting anti-VEGF treatment for nAMD with bevacizumab, as is mandatory in the Netherlands, delivers outcomes similar to those starting treatment with either ranibizumab or aflibercept, but at a cost of more frequent injections, and visits, and more frequent switching treatment to a second drug.